FDA Accepts Supplement Application for Depemokimab by GlaxoSmithKline
The FDA has accepted the supplemental application for BLA761458, a biologic from GlaxoSmithKline.
Therapeutic Area
Therapeutic area intelligence for IL-5 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.